Adult urologyPrevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less
Section snippets
Material and methods
From June 1998 to December 2001, 345 consecutive men diagnosed with hypogonadism after referral for sexual dysfunction underwent prostatic evaluation before initiating a program of testosterone replacement therapy. All patients had low levels of total testosterone (TT) or free testosterone (FT), or both, and a PSA level of 4.0 ng/mL or less. Men taking medications known to lower PSA (finasteride or dutasteride) were excluded from this analysis.
The serum determinations of TT and FT were obtained
Results
The characteristics of the study group are shown in Table I. The study included 345 men with a mean age of 58.9 years. Of these, 184 men (53.3%) had a TT level less than 300 ng/dL, and 327 (94.8%) had a FT level of less than 1.5 ng/dL. Of the 345 men, 23 were younger than 50 years, 12 had a TT level of 250 ng/dL or less, and 11 had TT level greater than 250 ng/dL. The PSA level was 4.0 ng/mL or less for all men, and the DRE findings were normal in 70.1%.
The biopsy results revealed 52 patients
Comment
The results of this retrospective study confirm and extend our previous findings that a sizable proportion of hypogonadal men has biopsy-detectable prostate cancer despite normal PSA levels.1 In addition, the combination of low serum testosterone and PSA level greater than 2.0 ng/mL appears to be particularly worrisome for the presence of cancer, because 30.2% of such men in this study had positive biopsy findings. Moreover, this study for the first time presents data showing that lower
Conclusions
This study has revealed that a substantial number of hypogonadal men have biopsy-detectable prostate cancer, even with normal DRE findings and PSA level of 4.0 ng/mL or less. The risk of cancer was doubled for men with the lowest testosterone values and was particularly worrisome when low testosterone levels were combined with PSA levels of 2.0 ng/mL or greater. The relationship between low serum testosterone and prostate cancer risk merits further investigation.
References (16)
- et al.
Is low serum testosterone a marker for high grade prostate cancer?
J Urol
(2000) - et al.
Pretreatment TT level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy
J Urol
(2003) - et al.
Testosterone as a predictor of pathological stage in clinically localized prostate cancer
J Urol
(2005) - et al.
Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer
J Urol
(2003) - et al.
Influence of radical prostatectomy on serum hormone levels
J Urol
(1998) - et al.
Occult prostate cancer in men with low serum testosterone levels
JAMA
(1996) - et al.
Pathological features of occult prostatic carcinoma in hypogonadal men
Prostate J
(2000) - et al.
High-grade prostate cancer is associated with low serum testosterone levels
Prostate
(2001)
Cited by (180)
Age 70 +/- 5 Years and Cancer-Specific Outcomes After Treatment of Localized Prostate Cancer: A Systematic Review
2024, International Journal of Radiation Oncology Biology PhysicsTestosterone Therapy and Prostate Cancer: Incorporating Low-Level Evidence into Practical Recommendations
2022, Urologic Clinics of North AmericaThe Pre-Testosterone Therapy Checklist
2022, Journal of Sexual MedicineDiscovering the role of androgens in urethral homeostasis and regeneration
2022, Scientific Advances in Reconstructive Urology and Tissue EngineeringPossible effects of low testosterone levels on olfactory function in males
2021, Brazilian Journal of Otorhinolaryngology
- 1
E. L. Rhoden is supported by Coordenação de Aperfeiçoamento Pessoal de Nível Superior of Brazil and is an I-C Reseacher from Conselho Nacional de Pesquisa, Brasil.